Lipocine (NASDAQ:LPCN) Stock Price Passes Below 200-Day Moving Average – What’s Next?

Lipocine Inc. (NASDAQ:LPCN)’s stock price crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $4.51 and traded as low as $2.09. Lipocine shares last traded at $2.09, with a volume of 13,317 shares changing hands.

Wall Street Analyst Weigh In

Several research analysts have commented on LPCN shares. Weiss Ratings downgraded Lipocine from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 18th. Wall Street Zen raised Lipocine from a “sell” rating to a “hold” rating in a research report on Saturday, July 18th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Lipocine has an average rating of “Reduce” and a consensus price target of $15.00.

Lipocine Stock Performance

The company has a market cap of $16.98 million, a P/E ratio of -1.15 and a beta of 0.46. The stock has a 50-day simple moving average of $2.26 and a 200 day simple moving average of $4.45.

Lipocine (NASDAQ:LPCN) last issued its earnings results on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.08. The business had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.21 million. Lipocine had a negative return on equity of 64.75% and a negative net margin of 755.39%. Sell-side analysts anticipate that Lipocine Inc. will post -1.91 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lipocine

Hedge funds have recently made changes to their positions in the business. Squadron Capital Management LLC bought a new stake in Lipocine in the fourth quarter valued at about $4,256,000. Eversept Partners LP acquired a new position in Lipocine in the first quarter worth about $2,357,000. Diadema Partners LP bought a new position in Lipocine during the fourth quarter worth about $2,095,000. AIGH Capital Management LLC acquired a new stake in Lipocine during the first quarter valued at approximately $1,598,000. Finally, Ikarian Capital LLC acquired a new stake in Lipocine during the fourth quarter valued at approximately $1,602,000. Institutional investors and hedge funds own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.